Standard Family Office LLC purchased a new stake in shares of InMode Ltd. (NASDAQ:INMD) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 462 shares of the healthcare company’s stock, valued at approximately $33,000.
A number of other large investors have also recently bought and sold shares of INMD. Public Employees Retirement Association of Colorado bought a new position in shares of InMode in the fourth quarter worth about $62,000. Steward Partners Investment Advisory LLC grew its holdings in InMode by 96.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,550 shares of the healthcare company’s stock valued at $121,000 after purchasing an additional 1,250 shares during the period. Citigroup Inc. acquired a new position in InMode during the fourth quarter valued at approximately $123,000. The PNC Financial Services Group Inc. boosted its holdings in shares of InMode by 11.4% in the first quarter. The PNC Financial Services Group Inc. now owns 2,450 shares of the healthcare company’s stock valued at $177,000 after buying an additional 250 shares during the period. Finally, HighTower Advisors LLC acquired a new position in shares of InMode in the first quarter valued at approximately $260,000. Institutional investors and hedge funds own 61.57% of the company’s stock.
Shares of INMD opened at $90.32 on Friday. The company has a market capitalization of $2.89 billion, a price-to-earnings ratio of 39.96 and a beta of 1.87. The company has a 50-day moving average of $82.52. InMode Ltd. has a fifty-two week low of $24.80 and a fifty-two week high of $93.91.
Several research firms have recently weighed in on INMD. Barclays began coverage on shares of InMode in a report on Monday, May 24th. They issued an “overweight” rating and a $92.00 price target for the company. Needham & Company LLC began coverage on shares of InMode in a report on Tuesday, May 18th. They issued a “buy” rating and a $94.00 price target for the company. UBS Group boosted their price objective on shares of InMode from $64.00 to $84.00 and gave the stock a “buy” rating in a research report on Thursday, February 11th. Robert W. Baird boosted their price objective on shares of InMode from $84.00 to $104.00 and gave the stock an “outperform” rating in a research report on Thursday, May 6th. Finally, Canaccord Genuity boosted their price objective on shares of InMode from $80.00 to $95.00 and gave the stock a “buy” rating in a research report on Thursday, May 6th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $91.33.
InMode Company Profile
InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments.
Featured Article: How to use beta for portfolio diversification
Want to see what other hedge funds are holding INMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for InMode Ltd. (NASDAQ:INMD).
Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with MarketBeat.com's FREE daily email newsletter.